# Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

> **NCT06408623** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 48 (estimated)

## Conditions studied

- Liver Cancer

## Interventions

- **DRUG:** chidamide combined with Sintilimab and bevacizumab

## Key facts

- **NCT ID:** NCT06408623
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-05-15
- **Primary completion:** 2025-05-15
- **Final completion:** 2026-05-15
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06408623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06408623, "Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06408623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*